ASR-3001, also known as 5-methoxy-N-isopropyl-N-allyltryptamine (5-MeO-iPALT), is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 5-methoxytryptamine families which is under development for the treatment of psychiatric disorders. It is a close analogue of related psychedelic tryptamines like 5-MeO-DALT, 5-MeO-DiPT, and 5-MeO-MiPT. The drug is taken orally.
Use and effects ASR-3001 is said to be orally active, fast- and short-acting, and to induce "an internal psychedelic cognitive state [or head space] with little or no sensory [or visual] involvement". More specifically, it is said to have an absence of open-eye and closed-eye visuals. These properties are expected to allow ASR-3001 to serve as a potential "entry point" for people reluctant to undergo a fully immersive psychedelic experience that includes visuals. ASR-3001 is said to be internally psychedelic as opposed to entactogenic. Its dose range is 8 to 14mg (or perhaps up to 10mg), its onset is within 15minutes or as fast as 6 to 8minutes, and its duration is short at about 1.5 to 2.5hours (90–150minutes). Along with 4-HO-DiPT, it appears to be one of the shortest-acting oral psychedelics known.
Interactions
Pharmacology Pharmacodynamics ASR-3001 acts as a non-selective agonist of the serotonin receptors. This includes of the serotonin 5-HT2A, 5-HT2B, 5-HT1A, 5-HT1B, and 5-HT6 receptors, whereas other serotonin receptors, such as the serotonin 5-HT2C receptor, were not described. Its values were 9.85nM at the serotonin 5-HT2A receptor, 46.8nM at the serotonin 5-HT1B receptor, 87.4nM at the serotonin 5-HT2B receptor, 420nM at the serotonin 5-HT6 receptor, and 642nM at the serotonin 5-HT1A receptor. The drug was also a very weak serotonin reuptake inhibitor ( = 6,840nM), but did not inhibit norepinephrine or dopamine reuptake. It showed little or no activity at various other sites as well.
Chemistry Synthesis The chemical synthesis of ASR-3001 has been described.
Analogues Analogues of ASR-3001 (5-MeO-iPALT) include isopropylallyltryptamine (iPALT; ASR-3003), 5-MeO-DMT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-MiPT, 5-MeO-EiPT, 5-MeO-PiPT, 5-MeO-MALT, and 5-MeO-EPT, among others. Other analogues include ASR-3002 (2-Me-iPALT), and ASR-3004 (PALT), among others.
History ASR-3001 was first described by 2023 and was patented the same year.
Society and culture Legal status Canada ASR-3001 is not an explicitly nor implicitly controlled substance in Canada as of 2025.
United States ASR-3001 is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Research ASR-3001 is under development by the Nicholas V. Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI). As of early 2025, it is in the preclinical research stage of development. The drug is the ASRI's most advanced developmental candidate.
See also Substituted tryptamine List of investigational hallucinogens and entactogens ASR-2001 (2CB-5PrO) 2C-T-17 and MiPT
References
External links ASR-3001 (5-MeO-ALIPT, 5-MeO-IPALT) - Isomer Design ASRI Expands Global Reach with Patent Filings for Innovative Empathogens, Tryptamines and Phenylalkylamines (May 28, 2024) - Alexander Shulgin Research Institute - PR Newswire